Sign in
APRE Stock Price, Chart, Stats & News
Aprea Therapeutics, Inc.
Save
4.64M
Market cap
–
Current P/E
–
Forward P/E
APRE chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 92.40% |
Operating margin | -4631.12% |
Pretax margin | -4409.16% |
Net margin | -4409.16% |
Effective tax rate | – |
ROA | -79.08% |
ROE | -93.72% |
D/E | – |
Interest coverage ratio | – |
APRE valuation
P/E | – |
P/S | 15.52x |
P/B | 0.40x |
P/CF | -0.40x |
P/FCF | -0.34x |
P/OCF | -0.40x |
PEG | -0.05x |
EV multiple | -1.46x |
About
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors.
Similar securities
Based on sector and market capitalization
Report issue